輝瑞擬以116億美元收購偏頭痛製藥商Biohaven
格隆匯5月10日丨據路透,輝瑞(PFE.US)週二表示,將以約116億美元現金收購偏頭痛藥物製造商Biohaven(BHVN.US),輝瑞將獲得Biohaven公司已獲批的藥物Rimegepant的使用權。Rimegepant屬於一種被稱為降鈣素基因相關肽(CGRP)抑制劑的偏頭痛藥物。輝瑞表示,將以每股148.50美元的現金價格收購Biohaven所有未發行的股票,這一價格比Biohaven最近的收盤價高出78.6%。輝瑞持有該公司2.6%的股份。輝瑞憑藉新冠疫苗和口服藥物Paxlovid的成功積累了大量現金,一些投資者預計,由於未來幾年該公司面臨關鍵藥物專利保護的損失,該公司將進行收購。Rimegepant在美國的市場名稱為Nurtec ODT,於2020年獲批用於治療急性偏頭痛發作,去年5月獲得了預防偏頭痛發作的更廣泛批准。這種療法在2021年帶來了4.625億美元的銷售額。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.